RAW 264.7 cells were cultured with high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, South Logan, UT, USA) containing 10% FBS (Hyclone) and 100 U/mL of penicillin/streptomycin (Thermo Fisher Scientific). A total of 5 × 103/well RAW264.7 cells at passages 3 to 5 were seeded into 24-well plates and induced by M-CSF (Peprotech, Cranbury, NJ, USA) and sRANKL (R&D Systems) at a concentration of 20 ng/mL for osteoclast differentiation. Human DPSC-derived exosomes were administrated with a final concentration of 5 × 107/mL.
To investigate the influence of TRPV4, the RAW 264.7 cells induced by M-CSF and sRANKL were treated with GSK219 (10 μM; Selleck, Houston, TX, USA), a specific TRPV4 inhibitor [46 (link)]. TRPV4 agonist GSK101 (Selleck Selleck, Houston, TX, USA) was delivered at a concentration of 100 nM [37 (link)]. DMSO was administrated as a control.
To investigate the influence of TRPV4, the RAW 264.7 cells induced by M-CSF and sRANKL were treated with GSK219 (10 μM; Selleck, Houston, TX, USA), a specific TRPV4 inhibitor [46 (link)]. TRPV4 agonist GSK101 (Selleck Selleck, Houston, TX, USA) was delivered at a concentration of 100 nM [37 (link)]. DMSO was administrated as a control.
Free full text: Click here
